Hearing improvement after bevacizumab for neurofibromatosis type 2

New England Journal of Medicine

Volumn 361, Issue 18, 2009, Pages 1810-

  Diao, Jian Sheng ^a   Xia, Wen Sen ^a   Guo, Shu Zhong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

ACOUSTIC NEURINOMA; HEARING IMPAIRMENT; HUMAN; LETTER; MONOTHERAPY; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HEARING LOSS; HUMANS; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350560341     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Wey JS, Fan F, Gray MJ, et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 2005;104:427-438 (Pubitemid 40993273)
2. Fan F, Wey JS, McCarty MF, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005;24:2647-2653 (Pubitemid 40593092)
3. Caye-Thomasen P, Baandrup L, Jacobsen GK, Thomsen J, Stangerup SE. Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 2003;113:2129-2134 (Pubitemid 38063834)
4. Caye-Thomasen P, Werther K, Nalla A, et al. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 2005;26:98-101. (Pubitemid 40130217)